Loading
Melbourne haematologist who led ALCANZA, the trial that showed brentuximab vedotin beats standard treatment for CD30-expressing cutaneous T-cell lymphoma.
Miles Prince is a haematologist at the Peter MacCallum Cancer Centre and Epworth Healthcare in Melbourne. He was first author of the 2017 Lancet report of ALCANZA, the international phase 3 trial in which brentuximab vedotin produced more lasting responses than physician's choice of methotrexate or bexarotene in previously treated CD30-positive mycosis fungoides or primary cutaneous anaplastic large-cell lymphoma, leading to the drug's approval in this setting.
| Title | Journal | Year |
|---|---|---|
| ALCANZA: brentuximab vedotin versus physician's choice in CD30-positive cutaneous T-cell lymphoma | The Lancet | 2017 |
Shares the tags lymphoma, trialist.
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tags lymphoma, trialist.
Shares the tags lymphoma, trialist.
Shares the tags lymphoma, trialist.
Shares the tags lymphoma, trialist.
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag lymphoma.
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag lymphoma.
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag lymphoma.